Symbols / ABUS Stock $4.39 +1.15% Arbutus Biopharma Corporation

Healthcare • Biotechnology • United States • NMS
ABUS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Ms. Lindsay Androski J.D., M.B.A.
Exch · Country NMS · United States
Market Cap 864.57M
Enterprise Value 770.87M
Income -33.50M
Sales 14.08M
FCF (ttm) -17.62M
Book/sh 0.40
Cash/sh 0.47
Employees 19
Insider 10d —
IPO Jul 26, 2007
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -26.56
PEG —
P/S 61.39
P/B 11.03
P/C —
EV/EBITDA -28.88
EV/Sales 54.74
Quick Ratio 15.52
Current Ratio 15.73
Debt/Eq 5.47
LT Debt/Eq —
EPS (ttm) -0.17
EPS next Y -0.17
EPS Growth —
Revenue Growth -33.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-03-23
ROA -14.94%
ROE -38.52%
ROIC —
Gross Margin -79.23%
Oper. Margin -7.27%
Profit Margin -237.88%
Shs Outstand 196.94M
Shs Float 125.75M
Insider Own 20.52%
Instit Own 66.31%
Short Float 13.42%
Short Ratio 8.78
Short Interest 17.74M
52W High 5.10
vs 52W High -13.92%
52W Low 2.94
vs 52W Low 49.32%
Beta 0.62
Impl. Vol. 12.50%
Rel Volume 0.34
Avg Volume 2.22M
Volume 750.86K
Target (mean) $5.21
Tgt Median $5.05
Tgt Low $4.99
Tgt High $5.59
# Analysts 3
Recom None
Prev Close $4.34
Price $4.39
Change 1.15%
About

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$5.21
Mean price target
2. Current target
$4.39
Latest analyst target
3. DCF / Fair value
$-1.61
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.39
Low
$4.99
High
$5.59
Mean
$5.21

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-11-14 main Chardan Capital Buy → Buy $5
2025-08-11 main Chardan Capital Buy → Buy $5
2025-03-28 main Chardan Capital Buy → Buy $5
2025-01-21 reit HC Wainwright & Co. Buy → Buy $5
2024-11-20 main Chardan Capital Buy → Buy $5
2024-11-18 reit HC Wainwright & Co. Buy → Buy $5
2024-11-07 reit HC Wainwright & Co. Buy → Buy $5
2024-11-07 main Chardan Capital Buy → Buy $5
2024-09-05 main Jefferies Buy → Buy $7
2024-08-02 main JMP Securities Market Outperform → Market Outperform $5
2024-06-07 reit HC Wainwright & Co. Buy → Buy $5
2024-06-06 reit HC Wainwright & Co. Buy → Buy $5
2024-06-05 main Chardan Capital Buy → Buy $4
2024-05-03 reit Chardan Capital Buy → Buy $4
2024-04-04 reit JMP Securities Market Outperform → Market Outperform $4
2024-03-01 reit Chardan Capital Buy → Buy $4
2024-03-01 main HC Wainwright & Co. Buy → Buy $5
2023-09-12 reit HC Wainwright & Co. Buy → Buy $6
2023-08-04 reit HC Wainwright & Co. Buy → Buy $6
2023-08-04 reit Chardan Capital Buy → Buy $6
News
RSS: Latest ABUS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-02 ANDROSKI LINDSAY J.D. Chief Executive Officer — 28,000 $0.00 $0
2026-02-02 NGUYEN TUAN Chief Financial Officer — 73,500 $0.00 $0
2025-02-14 NAFTZGER J CHRISTOPHER General Counsel — 54,300 $0.00 $0
2025-02-14 HASTINGS DAVID C Chief Financial Officer — 90,100 $0.00 $0
2025-02-14 SIMS KAREN Officer — 49,300 $0.00 $0
2025-02-04 NAFTZGER J CHRISTOPHER General Counsel — 11,333 $3.28 $37,206
2025-02-04 HASTINGS DAVID C Chief Financial Officer — 22,183 $3.28 $72,827
2025-02-04 SIMS KAREN Officer — 19,348 $3.28 $63,519
2024-08-14 MANCHESTER KEITH S Director — 8,846 $3.69 $32,637
2024-08-14 MANCHESTER KEITH S Director — 54,915 $0.56 $30,752
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
14.08
+128.21%
6.17
-65.98%
18.14
-53.51%
39.02
Operating Revenue
14.08
+128.21%
6.17
-65.98%
18.14
-53.51%
39.02
Operating Expense
41.13
-45.98%
76.14
-20.83%
96.17
-5.93%
102.24
Research And Development
25.24
-53.29%
54.04
-26.68%
73.70
-12.69%
84.41
Selling General And Administration
15.89
-28.11%
22.11
-1.63%
22.48
+26.02%
17.83
General And Administrative Expense
15.89
-28.11%
22.11
-1.63%
22.48
+26.02%
17.83
Other Gand A
15.89
-28.11%
22.11
-1.63%
22.48
+26.02%
17.83
Total Expenses
41.13
-45.98%
76.14
-20.83%
96.17
-5.93%
102.24
Operating Income
-27.05
+61.34%
-69.97
+10.33%
-78.03
-23.43%
-63.22
Total Operating Income As Reported
-38.16
+50.00%
-76.32
+2.28%
-78.10
-19.32%
-65.46
EBITDA
-33.04
+51.70%
-68.40
+3.64%
-70.99
-14.75%
-61.86
Normalized EBITDA
-22.62
+63.52%
-62.01
+12.59%
-70.94
-19.02%
-59.60
Reconciled Depreciation
0.36
-73.70%
1.38
-1.71%
1.40
-1.61%
1.43
EBIT
-33.40
+52.13%
-69.78
+3.60%
-72.39
-14.39%
-63.29
Total Unusual Items
-10.42
-62.98%
-6.39
-14431.82%
-0.04
+98.05%
-2.25
Total Unusual Items Excluding Goodwill
-10.42
-62.98%
-6.39
-14431.82%
-0.04
+98.05%
-2.25
Special Income Charges
-10.44
-64.46%
-6.34
-9095.65%
-0.07
+96.91%
-2.23
Restructuring And Mergern Acquisition
11.11
+75.08%
6.34
+9095.65%
0.07
-96.91%
2.23
Net Income
-33.50
+52.09%
-69.92
+4.02%
-72.85
-4.89%
-69.46
Pretax Income
-33.50
+52.09%
-69.92
+4.02%
-72.85
-12.05%
-65.01
Net Non Operating Interest Income Expense
3.97
-38.42%
6.45
+23.31%
5.23
+1022.10%
0.47
Interest Expense Non Operating
0.10
-29.20%
0.14
-70.15%
0.46
-73.41%
1.73
Net Interest Income
3.97
-38.42%
6.45
+23.31%
5.23
+1022.10%
0.47
Interest Expense
0.10
-29.20%
0.14
-70.15%
0.46
-73.41%
1.73
Interest Income Non Operating
4.07
-38.22%
6.58
+15.77%
5.69
+159.49%
2.19
Interest Income
4.07
-38.22%
6.58
+15.77%
5.69
+159.49%
2.19
Other Income Expense
-10.42
-62.98%
-6.39
-14431.82%
-0.04
+98.05%
-2.25
Gain On Sale Of Security
0.01
+128.57%
-0.05
-296.00%
0.03
+213.64%
-0.02
Tax Provision
—
0.00
0.00
-100.00%
4.44
Tax Rate For Calcs
0.00
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
+100.00%
-0.47
Net Income Including Noncontrolling Interests
-33.50
+52.09%
-69.92
+4.02%
-72.85
-4.89%
-69.46
Net Income From Continuing Operation Net Minority Interest
-33.50
+52.09%
-69.92
+4.02%
-72.85
-4.89%
-69.46
Net Income From Continuing And Discontinued Operation
-33.50
+52.09%
-69.92
+4.02%
-72.85
-4.89%
-69.46
Net Income Continuous Operations
-33.50
+52.09%
-69.92
+4.02%
-72.85
-4.89%
-69.46
Normalized Income
-23.08
+63.67%
-63.53
+12.75%
-72.81
-7.58%
-67.67
Net Income Common Stockholders
-33.50
+52.09%
-69.92
+4.02%
-72.85
-4.89%
-69.46
Otherunder Preferred Stock Dividend
—
—
—
0.00
Diluted EPS
-0.17
+55.26%
-0.38
+13.64%
-0.44
+4.35%
-0.46
Basic EPS
-0.17
+55.26%
-0.38
+13.64%
-0.44
+4.35%
-0.46
Basic Average Shares
191.60
+3.23%
185.61
+11.84%
165.96
+9.95%
150.94
Diluted Average Shares
191.60
+3.23%
185.61
+11.84%
165.96
+9.95%
150.94
Diluted NI Availto Com Stockholders
-33.50
+52.09%
-69.92
+4.02%
-72.85
-4.89%
-69.46
Earnings From Equity Interest
—
—
—
—
Gain On Sale Of PPE
0.67
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
94.62
-28.16%
131.71
-8.79%
144.40
-26.11%
195.42
Current Assets
94.46
-25.81%
127.32
-3.57%
132.03
-12.65%
151.14
Cash Cash Equivalents And Short Term Investments
91.47
-25.40%
122.62
-2.68%
126.00
-14.23%
146.91
Cash And Cash Equivalents
18.01
-50.43%
36.33
+38.22%
26.29
-14.59%
30.78
Other Short Term Investments
73.46
-14.87%
86.29
-13.46%
99.72
-14.14%
116.14
Receivables
1.45
-39.93%
2.41
+35.64%
1.78
+31.36%
1.35
Accounts Receivable
1.45
-39.93%
2.41
+35.64%
1.78
+31.36%
1.35
Prepaid Assets
—
—
—
—
Other Current Assets
1.54
-32.66%
2.28
-46.23%
4.25
+47.81%
2.87
Total Non Current Assets
0.16
-96.31%
4.39
-64.51%
12.37
-72.06%
44.28
Net PPE
0.03
-99.27%
4.36
-28.46%
6.09
-10.63%
6.81
Gross PPE
0.24
-98.59%
17.35
-3.54%
17.99
+2.13%
17.61
Accumulated Depreciation
-0.21
+98.36%
-13.00
-9.21%
-11.90
-10.17%
-10.80
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.24
-48.64%
0.48
+21.99%
0.39
+0.00%
0.39
Other Properties
—
8.29
-8.03%
9.01
+4.34%
8.63
Leases
0.00
-100.00%
8.59
+0.00%
8.59
+0.00%
8.59
Investments And Advances
—
0.00
-100.00%
6.28
-83.18%
37.36
Other Non Current Assets
0.13
+282.35%
0.03
—
0.10
Total Liabilities Net Minority Interest
18.04
-47.46%
34.34
-10.53%
38.38
-34.46%
58.57
Current Liabilities
6.01
-61.54%
15.62
-30.55%
22.49
-31.56%
32.86
Payables And Accrued Expenses
4.82
-36.29%
7.56
-26.36%
10.27
-35.92%
16.03
Payables
1.17
-49.35%
2.32
-28.14%
3.22
-8.44%
3.52
Accounts Payable
1.17
-49.35%
2.32
-28.14%
3.22
-8.44%
3.52
Current Accrued Expenses
3.65
-30.53%
5.25
-25.54%
7.05
-43.66%
12.51
Current Debt And Capital Lease Obligation
0.55
+13.25%
0.48
+13.65%
0.42
+14.25%
0.37
Current Capital Lease Obligation
0.55
+13.25%
0.48
+13.65%
0.42
+14.25%
0.37
Current Deferred Liabilities
0.00
-100.00%
7.57
-35.79%
11.79
-28.35%
16.46
Current Deferred Revenue
0.00
-100.00%
7.57
-35.79%
11.79
-28.35%
16.46
Other Current Liabilities
0.64
—
—
—
Total Non Current Liabilities Net Minority Interest
12.04
-35.72%
18.72
+17.78%
15.90
-38.17%
25.71
Long Term Debt And Capital Lease Obligation
0.20
-75.31%
0.81
-39.99%
1.34
-26.01%
1.81
Long Term Capital Lease Obligation
0.20
-75.31%
0.81
-39.99%
1.34
-26.01%
1.81
Non Current Deferred Liabilities
0.00
-100.00%
2.86
0.00
-100.00%
6.00
Non Current Deferred Revenue
0.00
-100.00%
2.86
0.00
-100.00%
6.00
Other Non Current Liabilities
11.84
-21.37%
15.05
+3.44%
14.55
-18.68%
17.90
Stockholders Equity
76.58
-21.35%
97.37
-8.16%
106.02
-22.53%
136.85
Common Stock Equity
76.58
-21.35%
97.37
-8.16%
106.02
-22.53%
136.85
Capital Stock
1,421.43
+0.81%
1,410.03
+4.46%
1,349.82
+2.36%
1,318.74
Common Stock
1,421.43
+0.81%
1,410.03
+4.46%
1,349.82
+2.36%
1,318.74
Preferred Stock
—
—
—
—
Share Issued
192.53
+1.35%
189.96
+11.83%
169.87
+7.88%
157.46
Ordinary Shares Number
192.53
+1.35%
189.96
+11.83%
169.87
+7.88%
157.46
Additional Paid In Capital
83.32
+1.55%
82.05
+0.96%
81.27
+12.24%
72.41
Retained Earnings
-1,380.07
-2.49%
-1,346.57
-5.48%
-1,276.65
-6.05%
-1,203.80
Gains Losses Not Affecting Retained Earnings
-48.10
+0.08%
-48.13
+0.59%
-48.42
+4.09%
-50.49
Other Equity Adjustments
-48.10
+0.08%
-48.13
+0.59%
-48.42
+4.09%
-50.49
Total Equity Gross Minority Interest
76.58
-21.35%
97.37
-8.16%
106.02
-22.53%
136.85
Total Capitalization
76.58
-21.35%
97.37
-8.16%
106.02
-22.53%
136.85
Working Capital
88.45
-20.81%
111.70
+1.97%
109.54
-7.39%
118.28
Invested Capital
76.58
-21.35%
97.37
-8.16%
106.02
-22.53%
136.85
Total Debt
0.75
-42.13%
1.29
-27.09%
1.77
-19.16%
2.19
Capital Lease Obligations
0.75
-42.13%
1.29
-27.09%
1.77
-19.16%
2.19
Net Tangible Assets
76.58
-21.35%
97.37
-8.16%
106.02
-22.53%
136.85
Tangible Book Value
76.58
-21.35%
97.37
-8.16%
106.02
-22.53%
136.85
Available For Sale Securities
—
—
—
37.36
Held To Maturity Securities
—
0.00
-100.00%
6.28
-83.18%
37.36
Investmentin Financial Assets
—
0.00
-100.00%
6.28
-83.18%
37.36
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-39.64
+38.88%
-64.85
+24.54%
-85.94
-143.06%
-35.36
Cash Flow From Continuing Operating Activities
-39.64
+38.88%
-64.85
+24.54%
-85.94
-143.06%
-35.36
Net Income From Continuing Operations
-33.50
+52.09%
-69.92
+4.02%
-72.85
-4.89%
-69.46
Depreciation Amortization Depletion
0.36
-73.70%
1.38
-1.71%
1.40
-1.61%
1.43
Depreciation
0.36
-73.70%
1.38
-1.71%
1.40
-1.61%
1.43
Depreciation And Amortization
0.36
-73.70%
1.38
-1.71%
1.40
-1.61%
1.43
Other Non Cash Items
-3.22
-742.12%
0.50
+114.99%
-3.34
+9.60%
-3.70
Stock Based Compensation
6.95
-22.62%
8.99
-3.39%
9.30
+29.50%
7.18
Asset Impairment Charge
2.81
+1583.23%
0.17
0.00
—
Operating Gains Losses
-0.67
—
-0.02
—
Net Foreign Currency Exchange Gain Loss
—
—
—
—
Gain Loss On Sale Of PPE
-0.67
0.00
+100.00%
-0.02
0.00
Change In Working Capital
-10.02
-254.29%
-2.83
+84.48%
-18.23
-162.35%
29.24
Change In Receivables
1.38
+317.22%
-0.63
-49.29%
-0.42
+6.40%
-0.45
Changes In Account Receivables
1.38
+317.22%
-0.63
-49.29%
-0.42
+6.40%
-0.45
Change In Prepaid Assets
1.70
-26.11%
2.30
+343.69%
-0.94
-138.81%
2.43
Change In Payables And Accrued Expense
-2.10
+22.24%
-2.71
+52.99%
-5.76
-210.39%
5.22
Change In Payable
—
—
—
5.22
Change In Account Payable
—
—
—
5.22
Change In Other Working Capital
-10.43
-668.90%
-1.36
+87.27%
-10.66
-147.49%
22.45
Change In Other Current Liabilities
-0.56
-29.53%
-0.43
+3.15%
-0.44
-9.63%
-0.41
Investing Cash Flow
15.58
-32.11%
22.95
-54.80%
50.77
+167.75%
-74.94
Cash Flow From Continuing Investing Activities
15.58
-32.11%
22.95
-54.80%
50.77
+167.75%
-74.94
Net PPE Purchase And Sale
0.36
+300.00%
-0.18
+81.58%
-0.99
-92.97%
-0.51
Purchase Of PPE
0.00
+100.00%
-0.18
+81.94%
-1.01
-96.88%
-0.51
Sale Of PPE
0.36
0.00
-100.00%
0.02
0.00
Capital Expenditure
—
-0.18
+81.94%
-1.01
-96.88%
-0.51
Net Investment Purchase And Sale
15.22
-34.22%
23.13
-55.31%
51.76
+169.54%
-74.43
Purchase Of Investment
-140.06
+1.02%
-141.51
-75.77%
-80.51
+38.27%
-130.43
Sale Of Investment
155.28
-5.69%
164.64
+24.47%
132.27
+136.20%
56.00
Financing Cash Flow
5.72
-89.00%
52.00
+69.66%
30.65
-3.67%
31.81
Cash Flow From Continuing Financing Activities
5.72
-89.00%
52.00
+69.66%
30.65
-3.67%
31.81
Net Common Stock Issuance
0.00
-100.00%
44.12
+47.81%
29.85
+46.88%
20.32
Proceeds From Stock Option Exercised
5.72
-27.33%
7.87
+890.31%
0.80
-93.08%
11.49
Changes In Cash
-18.34
-281.65%
10.09
+323.52%
-4.52
+94.25%
-78.48
Effect Of Exchange Rate Changes
0.01
+128.57%
-0.05
-296.00%
0.03
+213.64%
-0.02
Beginning Cash Position
36.33
+38.22%
26.29
-14.59%
30.78
-71.84%
109.28
End Cash Position
18.01
-50.43%
36.33
+38.22%
26.29
-14.59%
30.78
Free Cash Flow
-39.64
+39.05%
-65.03
+25.20%
-86.94
-142.40%
-35.87
Amortization Of Securities
-2.35
+25.07%
-3.13
-42.76%
-2.20
-3966.67%
-0.05
Common Stock Issuance
0.00
-100.00%
44.12
+47.81%
29.85
+46.88%
20.32
Issuance Of Capital Stock
0.00
-100.00%
44.12
+47.81%
29.85
+46.88%
20.32
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category